|
1
|
Rudin CM, Ismaila N, Hann CL, Malhotra N,
Movsas B, Norris K, Pietanza MC, Ramalingam SS, Turrisi AT III and
Giaccone G: Treatment of Small-cell lung cancer: American society
of clinical oncology endorsement of the american college of chest
physicians guideline. J Clin Oncol. 33:4106–4111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Denninghoff V, Russo A, de Miguel-Pérez D,
Malapelle U, Benyounes A, Gittens A, Cardona AF and Rolfo C: Small
cell lung cancer: State of the art of the molecular and genetic
landscape and novel perspective. Cancers (Basel). 13:17232021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oronsky B, Reid TR, Oronsky A and Carter
CA: What's new in SCLC? A Review. Neoplasia. 19:842–884. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Farago AF and Keane FK: Current standards
for clinical management of small cell lung cancer. Transl Lung
Cancer Res. 7:69–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tiseo M, Boni L, Ambrosio F, Camerini A,
Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E,
Passalacqua R, et al: Italian, multicenter, phase III, randomized
study of cisplatin plus etoposide with or without bevacizumab as
First-line treatment in Extensive-Disease Small-Cell lung cancer:
The GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 35:1281–1287. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jalal SI, Lavin P, Lo G, Lebel F and
Einhorn L: Carboplatin and etoposide with or without palifosfamide
in untreated Extensive-stage Small-Cell lung cancer: A multicenter,
adaptive, randomized phase III study (MATISSE). J Clin Oncol.
35:2619–2623. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Evans WK, Shepherd FA, Feld R, Osoba D,
Dang P and Deboer G: VP-16 and cisplatin as first-line therapy for
small-cell lung cancer. J Clin Oncol. 3:1471–147. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roth BJ, Johnson DH, Einhorn LH, Schacter
LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun
GO, et al: Randomized study of cyclophosphamide, doxorubicin, and
vincristine versus etoposide and cisplatin versus alternation of
these two regimens in extensive small-cell lung cancer: A phase III
trial of the southeastern cancer study group. J Clin Oncol.
10:282–291. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johal S, Hettle R, Carroll J, Maguire P
and Wynne T: Real-world treatment patterns and outcomes in
small-cell lung cancer: A systematic literature review. J Thorac
Dis. 13:3692–3707. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goldman JW, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab, with or without tremelimumab, plus
Platinum-etoposide versus Platinum-etoposide alone in First-line
treatment of Extensive-stage Small-cell lung cancer (CASPIAN):
Updated results from a randomised, controlled, Open-label, phase 3
trial. Lancet Oncol. 22:51–65. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
Extensive-Stage Small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk
Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC and Crofts T:
Phase III trial comparing supportive care alone with supportive
care with oral topotecan in patients with relapsed small-cell lung
cancer. J Clin Oncol. 24:5441–5447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baize N, Monnet I, Greillier L, Geier M,
Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, et
al: Carboplatin plus etoposide versus topotecan as Second-line
treatment for patients with sensitive relapsed small-cell lung
cancer: An Open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 21:1224–1233. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goto K, Ohe Y, Shibata T, Seto T,
Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, et
al: Combined chemotherapy with cisplatin, etoposide, and irinotecan
versus topotecan alone as second-line treatment for patients with
sensitive relapsed Small-cell lung cancer (JCOG0605): A
multicentre, Open-label, randomised phase 3 trial. Lancet Oncol.
17:1147–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zauderer M, Krug LM, Pietanza MC and
O'Rourke D: Leptomeningeal metastases from small cell lung cancer
responsive to temozolomide therapy. J Thorac Oncol. 5:1716–1717.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pietanza MC, Kadota K, Huberman K, Sima
CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny
AI, et al: Phase II trial of temozolomide in patients with relapsed
sensitive or refractory small cell lung cancer, with assessment of
methylguanine-DNA methyltransferase as a potential biomarker. Clin
Cancer Res. 18:1138–1145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zauderer MG, Drilon A, Kadota K, Huberman
K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg
MS, et al: Trial of a 5-day dosing regimen of temozolomide in
patients with relapsed small cell lung cancers with assessment of
methylguanine-DNA methyltransferase. Lung Cancer. 86:237–240. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pietanza MC, Waqar SN, Krug LM, Dowlati A,
Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto
J, et al: Randomized, Double-blind, phase II study of temozolomide
in combination with either veliparib or placebo in patients with
Relapsed-sensitive or refractory Small-cell lung cancer. J Clin
Oncol. 36:2386–2394. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lok BH, Gardner EE, Schneeberger VE, Ni A,
Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell
SN, et al: PARP inhibitor activity correlates with SLFN11
expression and demonstrates synergy with temozolomide in small cell
lung cancer. Clin Cancer Res. 23:523–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farago AF, Yeap BY, Stanzione M, Hung YP,
Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, et
al: Combination olaparib and temozolomide in relapsed Small-cell
lung cancer. Cancer Discov. 9:1372–1387. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kalemkerian GP, Akerley W, Bogner P,
Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R,
Grecula JC, et al: Small cell lung cancer. J Natl Compr Canc Netw.
11:78–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ahmad I, Chufal KS, Gupta S and Bhatt CP:
Defining limited stage small cell lung cancer: A radiation
oncologist's perspective. BMJ Case Rep. 2018:bcr20172237082018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han J, Qiu M, Su L, Wu C, Cheng S, Zhao Z,
Li D, Wang M, Tao W and Du S: Response and safety of whole-brain
radiotherapy plus temozolomide for patients with brain metastases
of non-small-cell lung cancer: A meta-analysis. Thorac Cancer.
12:3177–3183. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duan H, Zheng SY, Zhou T, Cui HJ and Hu
KW: Temozolomide plus whole brain radiotherapy for the treatment of
non-small-cell lung cancer patients with brain metastases: A
protocol of an updated systematic review and meta-analysis.
Medicine (Baltimore). 99:e184552020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu L, Wang Y, Li L, Yu L, Liu L, Qu B and
Zhang X: 125I Radiotherapy combined with metronomic chemotherapy
may boost the abscopal effect, leading to complete regression of
liver metastasis in an SCLC patient with a 58.5-month OS: A case
report. Front Oncol. 13:9651662023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei J, Dong XF, Hu ZL, Tang S and Lu YF:
Successful treatment with temozolomide in an elderly woman with
advanced pulmonary Large-cell neuroendocrine carcinoma: A case
report. Medicine (Baltimore). 97:e133182018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Furuse K, Kubota K, Kawahara M, Takada M,
Kimura I, Fujii M, Ohta M, Hasegawa K, Yoshida K, Nakajima S, et
al: Phase II study of vinorelbine in heavily previously treated
small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group.
Oncology. 53:169–172. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rapti A, Agelidou A, Stergiou I, Agelidou
M, Nikolakopoulos I, Varthalitis J, Kalykaki A, Chainis K, Tzanakis
N and Georgoulias V; Lung Cancer Committee of the Hellenic Oncology
Research Group (HORG), : Combination of vinorelbine plus
gemcitabine in previously treated patients with small cell lung
cancer: A multicentre phase II study. Lung Cancer. 49:241–244.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dudek AZ, Leśniewski-Kmak K, Bliss RL,
Brunstein C, Condon DL and Kratzke RA: Pilot phase II study of
gemcitabine and vinorelbine in patients with recurrent or
refractory small cell lung cancer. Lung. 183:43–52. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirose Y, Berger MS and Pieper RO:
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates
temozolomide-induced toxicity in a p53-independent manner in human
glioblastoma cells. Cancer Res. 61:5843–5849. 2001.PubMed/NCBI
|
|
32
|
Günther W, Pawlak E, Damasceno R, Arnold H
and Terzis AJ: Temozolomide induces apoptosis and senescence in
glioma cells cultured as multicellular spheroids. Br J Cancer.
88:463–469. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Würstle S, Schneider F, Ringel F, Gempt J,
Lämmer F, Delbridge C, Wu W and Schlegel J: Temozolomide induces
autophagy in primary and established glioblastoma cells in an EGFR
independent manner. Oncol Lett. 14:322–328. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zou Y, Wang Q, Li B, Xie B and Wang W:
Temozolomide induces autophagy via ATM-AMPK-ULK1 pathways in
glioma. Mol Med Rep. 10:411–416. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yung WK, Prados MD, Yaya-Tur R, Rosenfeld
SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill
AM, et al: Multicenter phase II trial of temozolomide in patients
with anaplastic astrocytoma or anaplastic oligoastrocytoma at first
relapse. Temodal Brain Tumor Group. J Clin Oncol. 17:2762–2771.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baumert BG, Hegi ME, van den Bent MJ, von
Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn
MJB, Hassel MB, et al: Temozolomide chemotherapy versus
radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): A
randomised, open-label, phase 3 intergroup study. Lancet Oncol.
17:1521–1532. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee SY: Temozolomide resistance in
glioblastoma multiforme. Genes Dis. 3:198–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu W, Klockow JL, Zhang M, Lafortune F,
Chang E, Jin L, Wu Y and Daldrup-Link HE: Glioblastoma Multiforme
(GBM): An overview of current therapies and mechanisms of
resistance. Pharmacol Res. 171:1057802021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang X, Chen JX, Liu JP, You C, Liu YH and
Mao Q: Gain of function of mutant TP53 in glioblastoma: Prognosis
and response to temozolomide. Ann Surg Oncol. 21:1337–1344. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Norden AD, Lesser GJ, Drappatz J, Ligon
KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor
TT, et al: Phase 2 study of Dose-intense temozolomide in recurrent
glioblastoma. Neuro Oncol. 15:930–935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Binabaj MM, Bahrami A, ShahidSales S,
Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K and Avan A: The
prognostic value of MGMT promoter methylation in glioblastoma: A
meta-analysis of clinical trials. J Cell Physiol. 233:378–386.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hudson AL, Parker NR, Khong P, Parkinson
JF, Dwight T, Ikin RJ, Zhu Y, Chen J, Wheeler HR and Howell VM:
Glioblastoma recurrence correlates with increased APE1 and
polarization toward an Immuno-suppressive microenvironment. Front
Oncol. 8:3142018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tan MSY, Sandanaraj E, Chong YK, Lim SW,
Koh LWH, Ng WH, Tan NS, Tan P, Ang BT and Tang C: A STAT3-based
gene signature stratifies glioma patients for targeted therapy. Nat
Commun. 10:36012019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
George J, Lim JS, Jang SJ, Cun Y, Ozretić
L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, et al:
Comprehensive genomic profiles of small cell lung cancer. Nature.
524:47–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Egaña L, Auzmendi-Iriarte J, Andermatten
J, Villanua J, Ruiz I, Elua-Pinin A, Aldaz P, Querejeta A,
Sarasqueta C, Zubia F, et al: Methylation of MGMT promoter does not
predict response to temozolomide in patients with glioblastoma in
Donostia Hospital. Sci Rep. 10:184452020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Madan R and Goyal S: Temozolomide induced
cutaneous reaction. Neurol India. 70:435–443. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gilbar PJ, Pokharel K and Mangos HM:
Temozolomide-induced aplastic anaemia: Case report and review of
the literature. J Oncol Pharm Pract. 27:1275–1280. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Maldonado F, Limper AH, Lim KG and Aubrey
MC: Temozolomide-associated organizing pneumonitis. Mayo Clin Proc.
82:771–773. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ma W, Li N, An Y, Zhou C, Bo C and Zhang
G: Effects of temozolomide and radiotherapy on brain metastatic
tumor: A systematic review and Meta-analysis. World Neurosurg.
92:197–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gong L, Yin Y, Chen C, Wan Q, Xia D, Wang
M, Pu Z, Zhang B and Zou J: Characterization of EGFR-reprogrammable
Temozolomide-resistant cells in a model of glioblastoma. Cell Death
Discov. 8:4382022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Klotz U: Pharmacokinetics and drug
metabolism in the elderly. Drug Metab Rev. 41:67–76. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chow MC, Chambers P, Singleton G, Patel J,
Cooper S, Mythen C, Bautista-González E, Chisnall G, Djellouli N,
Thwaites B, et al: Global changes to the chemotherapy service
during the covid-19 pandemic. J Oncol Pharm Pract. 27:1073–1079.
2021. View Article : Google Scholar : PubMed/NCBI
|
